Kornimate/medical-research-clean huggingface dataset:
impact of supportive care on the experience of hospitalization of patients staying in the protected area of the department of blood diseases

Conditions: Acute Leukemia; Hematopoietic Stem Cell Transplantation (SCT); Aplasia

Summary: patients with acute leukemia or received sct are hospitalized in protected area, at least for 28 days. in this area, there is some rules like: controlled-visit, protective-clothing....so patient are in social and familial isolation condition. during their hospitalization, patients are confront to aggressive treatment and psychological distress related to potentially death. emergency hospitalization, illness, controlled environment, aggressive treatment and potential complications place patients in a context of anxiety-provoking. aesthetic therapy is a new supportive care in cancer therapy access on improving well-being, relaxation and body image. this supportive care is already used in cancerology department, particularly in breast cancer patients. in our department, a few patient received aesthetic care during their hospitalization and they appreciated these sessions and impact on well-being was immediately. moreover only 6 sessions was proposed and effect on anxiety wasn't measurable aesthetic care improve well-being but impact on anxiety is unknown. in this study we evaluate the impact off socio aesthetic on the quality off life and anxiety. we evaluate this impact by 3 questionnaires at 3 times during hospitalization.


Eligibility criteria:
inclusion criteria: * patient (male or female) ≥18 years old * hospitalized patient in restricted area than 21 days * patient with acute leukemia (induction or relapse) * patient hospitalized for hematopoietic stem cell transplantation * written inform consent must be obtained before inclusion and randomization * patient affiliated to and covered by social security for standard care exclusion criteria: * patient hospitalized for another disease * inability to receive study information and/or understand/speak french * inability to give informed consent * legal incapacity (people in jail) or under supervision (i.e. guardianship or curatorship) * already include in this study on a previous hospitalization

Keywords: aesthetic care transplant well-being anxiety supportive care
intubation-induced decrease in heart rate as an indicator for intraoperative bradycardia

Conditions: Tracheal Intubation; Airway Management; Heart Rate

Summary: this prospective observational study aims to determine, if an tracheal intubation-related decrease in heart rate is associated with intraoperative reflex bradycardia in patients undergoing microlaryngoscopy (mls) in general anesthesia.

small studies and case series reported precipitous bradycardia or even asystole due to reflex vagal activity during tracheal intubation and/or laryngoscopy attributable to a so called laryngocardiac reflex (reflex bradycardia); however, larger systematic trials are still lacking. for the purpose of mls, ent surgeons frequently apply suspension laryngoscopy (kleinsasser laryngoscope) in order to visualize the glottis and to enable surgery. severe bradycardia has been reported during mls that has been suspected to be induced by reflex vagal activity possibly promoted by the superior laryngeal nerve. it is still unknown, which patients are at risk for relevant intraoperative bradycardia and moreover, which patients might benefit from preemptive measures such as prophylactic application of positive chronotropic drugs like atropine sulfate, epinephrine or glycopyrrolate. predictive factors for mls-induced intraoperative bradycardia have not systematically been investigated yet. in particularly, it is unknown, if patients that present with a preoperative tracheal intubation-related decrease in heart rate have a predisposition for intraoperative reflex bradycardia during mls. this prospective observational study aims to determine, if an tracheal intubation-related decrease in heart rate is associated with intraoperative reflex bradycardia in patients undergoing microlaryngoscopy (mls) in general anesthesia. moreover, if we find a positive association, we further aim to determine the predictive value of intubation-relatd bradycardia.

Eligibility criteria:
inclusion criteria: * patients requiring general anesthesia with tracheal intubation for elective mls * age ≥ 18 exclusion criteria: * pregnant or breastfeeding women * confirmed indications for awake fiberoptic intubation * planned endotracheal intubation without deep anesthesia or neuromuscular blocking agents (e.g. awake videolaryngoscopy) * patients at risk for pulmonary aspiration who qualify for rapid sequence induction * cardiac pacemaker * atrial fibrillation * denial of consent

Keywords: laryngoscopy bradycardia microlaryngoscopy
a phase 3 study of ibrutinib (pci-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (pfs) as compared to treatment with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll)

study pcyc-1112-ca is a randomized, multicenter, open-label, phase 3 study of the bruton's tyrosine kinase (btk) inhibitor ibrutinib (pci-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. patients randomized to the ofatumumab arm may be considered to receive next subsequent therapy with ibrutinib.

Eligibility criteria:
inclusion criteria: * ecog performance status of 0-1. * diagnosis of cll or sll that meets iwcll 2008 criteria. * active disease meeting at least 1 of the iwcll 2008 criteria for requiring treatment. * must have received at least one prior therapy for cll/sll. * considered not appropriate for treatment or retreatment with purine analog based therapy. * measurable nodal disease by ct. * patients must be able to receive outpatient treatment and laboratory monitoring at the institution that administers study drug for the entire study. exclusion criteria: * known cns lymphoma or leukemia. * no documentation of cytogenetic and/or fish in patient records prior to first dose of study drug. * any history of richter's transformation or prolymphocytic leukemia. * uncontrolled autoimmune hemolytic anemia (aiha) or idiopathic thrombocytopenia purpura (itp). * prior exposure to ofatumumab or to ibrutinib. * prior autologous transplant within 6 months prior to first dose of study drug. * prior allogeneic stem cell transplant within 6 months or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug. * history of prior malignancy, with the exception of certain skin cancers and malignancies treated with curative intent and with no evidence of active disease for more than 3 years. * serologic status reflecting active hepatitis b or c infection. * unable to swallow capsules or disease significantly affecting gastrointestinal function. * uncontrolled active systemic fungal, bacterial, viral, or other infection. * history of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug. * requires anticoagulation with warfarin.

Keywords: chronic sll cll ofatumumab ibrutinib resonate phase iii leukemia lymphoma
efficacy and safety of terbinafine film forming solution in patients with tinea pedis

Conditions: Tinea Pedis

Summary: this study will compare the efficacy and safety of a single dose of terbinafine film forming solution 1% with a single dose of placebo film forming solution in the treatment of tinea pedis.


Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with interdigital tinea pedis infection, with clinical diagnosis meeting required baseline total sign \& symptom score and positive microscopy exclusion criteria: * allergy to the allylamine class of antimycotics or excipients in the formulation. * chronic, hyperkeratotic plantar (moccasin) tinea pedis * other fungal disease or intertrigo * other abnormal findings on the affected foot * systemic antifungal or antimicrobial treatment within the last 3 months * topical treatment for skin lesions on feet within the last 3 months * diabetes mellitus and peripheral artery occlusive disease

Keywords: tinea pedis terbinafine film forming solution
uniportal tubeless vats for the evaluation of biopsy for second-generation sequencing in patients with advanced nsclc

Conditions: NSCLC; Biopsy Technique; VATS; CT Guided Puncture Biopsy; NGS

Summary: the study is a single-center, prospective, open-label randomized controlled study. this study evaluates the eligibility rate of different biopsy methods (tubeless tubeless vats vs. ct guided fine needle aspiration) for the detection of molecular genetic characteristics of peripheral nsclc next-generation sequencing, and its main purpose is to evaluate the use of tumor gene profiling (ngs) the best biopsy technique, the first affiliated hospital of guangzhou medical university is the research center. it is expected to be completed between 2021-3-1 and 2023-3-1.


Eligibility criteria:
inclusion criteria: * informed consent is obtained * assessed by more than 2 surgeons, patients whose lesions can be achieved by tubeless single-port thoracoscopic surgical biopsy exclusion criteria: * history of other malignant tumors. * the general condition is not suitable for puncture, bronchoscopy, or surgery (such as cardiopulmonary dysfunction, high risk of bleeding, allergy to anesthetics, confusion, inability to exercise, etc.) * history of lung surgery, tuberculosis and coal mine work experience, etc. may cause severe chest adhesions; other situations that conflict with the biopsy process

Keywords: nsclc biopsy technique vats ct guided puncture biopsy ngs
evaluating the effect of mucinex® 1200 mg on mucociliary and cough clearance from the human lung

Conditions: Mucociliary Clearance

Summary: the purpose of this research study is to test the ability of mucinex, an oral, over-the-counter, fda approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). the study will also monitor the metabolism of the drug by the subject's body.


Eligibility criteria:
inclusion criteria: * healthy * non smoker * bmi 19-29 * normal lung function exclusion criteria: * pregnant * smokers * any illness

Keywords: healthy nonsmokers
a research study to compare blood levels of cagrilintide and semaglutide after single doses of different versions of injectable cagrisema in adults with overweight or obesity

Conditions: Obesity

Summary: this study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of cagrisema. cagrisema is a medicine that combines two medicines called cagrilintide and semaglutide. it is still being tested in studies and is not yet available for doctors to prescribe. participants will get an injection with each of the two versions of cagrisema at two different times at the clinic. like all medicines, the study medicine may have side effects. the study will last for about 18 weeks.


Eligibility criteria:
inclusion criteria: * male or female. * aged 18-64 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 27.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. overweight should be due to excess adipose tissue, as judged by the investigator. - considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * known or suspected hypersensitivity to study intervention(s) or related products. * previous dosing with an amylin analogue. * presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions. * female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method. * glycosylated haemoglobin (hba1c) greater than or equal to (\>=) 6.5 percent (48 millimoles per mole \[mmol/mol\]) at screening.
pilot study to determine the safety and efficacy of gardasil against the human papilloma virus (hpv) in hiv-infected men

Conditions: Anal Cancer; HIV Infections

Summary: this study will investigate the efficacy and safety of the quadrivalent vaccine (gardasil) against the human papilloma virus (hpv) in hiv (human immunodeficiency virus) infected males.

this is a prospective pilot study that will attempt to enroll approximately 150-200 hiv-infected males followed regularly in the id primary care clinic at the va long beach healthcare system. all consenting patients will be given the hpv vaccine (gardasil) in three intramuscular injections. baseline antibody titers to hpv strains 16 and 18 will be obtained at day 0 and repeat levels will be obtained approximately 8 weeks after the completion of the vaccination series to determine whether patients without antibodies at baseline have now produced antibodies, or to determine the change in antibody levels in those patients who have evidence of antibodies prior to the first injection of the vaccine. patients will undergo routine anal pap smear with hpv dna testing at baseline and another pap smear/hpv test approximately 8 weeks after completion of the series. patients will report any side effects of the vaccine to the pi. patients will have blood work to monitor hiv-1 viral load and cd4 lymphocytes counts at various points during the study.

Eligibility criteria:
inclusion criteria: * male veterans * age 18 or older * hiv-positive * seen regularly in the id primary care clinic at the va long beach healthcare system exclusion criteria: * none

Keywords: hpv hiv gardasil vaccine
canadian multicenter observational study of tysabri in early relapsing remitting multiple sclerosis participants

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: the primary objective of the study is to evaluate the impact of early treatment with tysabri in relapsing remitting multiple sclerosis (rrms) participants on their quality of life (qol) as measured by multiple sclerosis impact scale-29 (msis-29) over 2 years. the secondary objectives of the study are: to evaluate the impact of early treatment with tysabri in rrms participants over 2 years on the following: annualized relapse rate (arr), expanded disability status scale (edss), work productivity, quality of life (qol) by euroqol 5-dimension questionnaire (eq-5d), qol by subject global assessment of wellbeing visual analog scale (vas) and to evaluate clinical disease-free status (relapses, edss) over 2 years.


Eligibility criteria:
key inclusion criteria: * ability to understand the purpose and risks of the study and provide signed and dated informed consent. * documented diagnosis of relapsing multiple sclerosis (mcdonald 2010 criteria). * must have an expanded disability status scale (edss) score from 0 to 4.0, inclusive. * must satisfy the approved therapeutic indications for tysabri as per product monograph. * must either be treatment naïve or have been treated with disease modifying therapy dmt(s) (such as, but not limited to, avonex, betaseron, rebif, copaxone, extavia, tecfidera and/or gilenya) for ≤5 years total prior to date of informed consent. * decision to treat with tysabri must precede enrollment. key exclusion criteria: * any prior treatment with tysabri. * contraindications to treatment with tysabri as described in the product monograph. * history of progressive multifocal leukoencephalopathy (pml) or other opportunistic infections, or an increased risk for such infections. * history of diagnosis of primary progressive multiple sclerosis \[ppms\] and/or secondary progressive multiple sclerosis \[spms\]. * receiving immunomodulatory or immunosuppressive therapy. * prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab). * immunocompromised at the time of enrollment. * known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible). * women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception. * inability to comply with study requirements. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: quality of life
isolated fetal splenic cyst : prenatal diagnosis and postnatal evolution

Conditions: Pregnant Women

Summary: the aim of this study was to describe prevalence, radiologic and ultrasound evolution during pregnancy, postnatal evolution and treatment strategy in case of isolated fetal spelnic cyst

the aim of this study was to describe prevalence, radiologic and ultrasound evolution during pregnancy, postnatal evolution and treatment strategy in case of isolated fetal spelnic cyst. the investigators performed a retrospective study in the montpellier prenatal diagnosis centre between 2007 and 2017. all pregnant women referred to this unit after routine ultrasound examination with a suspected splenic cyst were included. participant all benefit a reference ultrasound to perform a detailed morphological examination. in any doubt about diagnosis, a mri exam wad proposed. then patient were followed regularly. at birth, all newborn babys had medical examination to search early complication. then, children had a surgical consultation and regular ultrasound examinations were performed.

Eligibility criteria:
inclusion criteria: * pregnent women with an isolated suspected fetal splenic cyst between 2007 and 2017 in montpellier prenatal diagnosis center exclusion criteria: * all others fetal diagnosis

Keywords: fetal splenic cyst differential diagnosis evolution and complication
marker assisted selective therapy in rare cancers: knowledge database establishing registry asia

Conditions: Rare Malignant Neoplasm

Summary: this is a registry study that aims to collect patients' data with advanced-stage rare cancer in asia-pacific region. data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. the relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.


Eligibility criteria:
inclusion criteria: 1. patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (defined in protocol.) 2. patients with advanced stage cancer. exclusion criteria: 1. patients with complications of cognitive impairment.

Keywords: rare cancer rare subtype registry asia next-generation sequencing
efficacy and safety study of calcipotriol betamethasone plus calcipotriol in sequential therapy to psoriasis

Conditions: Psoriasis

Summary: evaluate the efficacy and safety of calcipotriol betamethasone ointment and calcipotriol ointment in sequential therapy

1.240 subjects will be randomized 1:1:1 divided into the 3 groups 2.week0 to week4,each group were treated with calcipotriol betamethasone ointment 3.week4 to week12, the there group were respectively treated with calcipotriol betamethasone ointment,calcipotriol ointment and urea cream 4.the efficacy and safety were evaluated at the baseline, as well as 1, 4, 8 and 12 weeks after the beginning of treatment.

Eligibility criteria:
inclusion criteria: 1. subjects who signed informed consent form； 2. male or female subjects 18-65 years of age； 3. clinically confirmed diagnosis of plaque psoriasis as per the diagnostic criteria for psoriasis vulgaris specified in clinical dermatology. 4. involved area 1-10% of the body surface area. exclusion criteria: 1. incompliance with the diagnosis of plaque psoriasis or plaque area \> 10% of the body surface area. 2. erythrodermic psoriasis, psoriasis arfhropathica or pustular psoriasis; 3. known allergy to any component of the test or control drug； 4. concomitant allergic skin disease such as eczema， contact dermatitis and urticaria, or other serious and/or extensive skin disease； 5. systemic medication or ultraviolet therapy for psoriasis within 4 weeks prior to study initiation； 6. topical use of external drug for psoriasis within 2 weeks prior to study initiation； 7. women of child-bearing potential who are pregnant, plan to become pregnant during study or are lactating； 8. glucocorticoid or immunodepressant, or hypoleukemia due to tumor or chemotherapy within the last 4 weeks； 9. serious life-threatening condition that allows a life expectancy of less than 2 months； 10. inability to guarantee taking medications and completing visits as scheduled during the study; 11. serious infection that is not suitable for external treatment； 12. any other condition that the investigator deems unsuitable for entering the study.
evaluating the psychophysiological effects of a smartphone-based mindfulness task

Conditions: Chronic Pain; Depression, Anxiety

Summary: the aim of the present study is to evaluate the psychophysiological effects of a smart phone based mindfulness meditation app (mma) for individuals with clinically significant symptoms of major depression and/or anxiety, or symptoms of chronic pain. specifically, the study aims to examine parasympathetic tone using hrv (primary outcome), mind-wandering and present awareness, mood symptoms, and breath focus in groups of participants who self-report clinically significant symptoms of depression and/or anxiety (da), chronic pain symptoms (cp), as well as control participants who do not meet our criteria for either (controls (c). all study groups will be randomized to a mindfulness meditation app (mma+) condition or a mindfulness meditation condition without the app (mma-) after a brief stress-induction procedure.


Eligibility criteria:
inclusion criteria: * york university students exclusion criteria: * individuals with diagnosed cardiac conditions (e.g. coronary artery disease, arrhythmias etc) will be excluded due to confounds with heart rate variability assessment